Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Antiparkinsonian

or Empathogen

or PDE5 Inhibitor

Use the filters below to narrow your results.

4-FA (1) · 5-APB (1) · 5-MAPB (1) · 6-APB (1) · 6-APDB (1) · Amantadine (1) · Apomorphine (1) · Avanafil (1) · Benztropine (1) · Biperiden (1) · Bromocriptine (1) · Butylone (1) · Cabergoline (1) · Carbidopa/levodopa (1) · Entacapone (1) · Ephylone (1) · Ethylone (1) · Levodopa (1) · MDA (1) · MDAI (1) · MDEA (1) · MDMA (1) · Mephedrone (1) · Methylone (1) · Opicapone (1) · PMA (1) · PMMA (1) · Rasagiline (1) · Rotigotine (1) · Safinamide (1) · Selegiline (1) · Sildenafil (1) · Tadalafil (1) · Tolcapone (1) · Trihexyphenidyl (1) · Vardenafil (1)

None (17) · Akineton (1) · Apokyn (1) · Artane (1) · Azilect (1) · Cialis, Adcirca (1) · Cogentin (1) · Comtan (1) · Dostinex (1) · Eldepryl (1) · Levitra, Staxyn (1) · Neupro (1) · Ongentys (1) · Parlodel (1) · Sinemet (1) · Stendra (1) · Symmetrel (1) · Tasmar (1) · Viagra, Revatio (1) · Xadago (1)

Central and peripheral COMT inhibitor (1) · D1/D2/D3 receptor agonist (1) · D2 agonist; D1 partial agonist (1) · D2 receptor agonist (1) · Dopamine precursor (1) · Dopamine precursor + DOPA decarboxylase inhibitor (1) · Irreversible selective MAO-B inhibitor (2) · MAO inhibitor; monoamine releasing agent (1) · MAO inhibitor; serotonin releasing agent (1) · MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) · Monoamine releasing agent (3) · Monoamine releasing agent; 5-HT2A agonist (1) · Monoamine releasing agent; serotonergic at higher doses (1) · Muscarinic receptor antagonist (1) · Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) · NMDA antagonist; dopamine releasing agent (1) · Non-selective dopamine receptor agonist (1) · Once-daily COMT inhibitor (1) · Peripheral COMT inhibitor (1) · Selective inhibitor of PDE5 with a substantially longer half-life than other PDE5 inhibitors, allowing once-daily continuous dosing. (1) · Selective inhibitor of PDE5. Slightly higher PDE5/PDE6 selectivity vs sildenafil (less visual side effect) but more PDE1 cross-activity (occasional QT effects at high doses). (1) · Selective inhibitor of phosphodiesterase type 5 (PDE5), preventing cGMP breakdown in vascular smooth muscle. In the corpus cavernosum, potentiates the NO/cGMP cascade triggered by sexual stimulation. (1) · Selective inhibitor of phosphodiesterase type 5 (PDE5); increases cGMP in cavernous smooth muscle, producing erection in response to sexual stimulation. (1) · Selective M1 muscarinic antagonist (1) · Serotonin releasing agent (2) · Serotonin releasing agent; 5-HT2A agonist (3) · Serotonin/dopamine/norepinephrine releasing agent; 5-HT2A agonist (1) · Serotonin/norepinephrine/dopamine releasing agent (3)

None (32) · '"`UNIQ--vote-00000040-QINU`"' (1) · '"`UNIQ--vote-00000669-QINU`"' (1) · '"`UNIQ--vote-00000705-QINU`"', '"`UNIQ--vote-00000706-QINU`"' (1) · '"`UNIQ--vote-00000738-QINU`"', '"`UNIQ--vote-00000739-QINU`"', '"`UNIQ--vote-0000073A-QINU`"' (1)

None (32) · 10 mg PRN; 2.5–5 mg daily for continuous coverage / BPH (1) · 10 mg ~1 h before sexual activity (1) · 100 mg ~15 min before sexual activity (1) · 50 mg ~1 h before sexual activity (ED); 20 mg TID (PAH) (1)

None (32) · 2.5, 5, 10, 20 mg tabs (1) · 2.5, 5, 10, 20 mg tabs (Levitra); 10 mg ODT (Staxyn) (1) · 25, 50, 100 mg tabs (Viagra); 20 mg tabs and 10 mg/mL oral suspension (Revatio) (1) · 50, 100, 200 mg tabs (1)

None (32) · 100 mg/d (ED); 20 mg TID (PAH) (1) · 20 mg/d (1) · 20 mg/d (ED, PRN); 5 mg/d (daily / BPH); 40 mg/d (PAH) (1) · 200 mg/d (100 mg/d if on CYP3A4 inhibitors) (1)

None (32) · IV (Revatio) (1) · Oral (4)

None (32) · 30 min (1) · 30–60 min (1) · ~15 min (fastest of the PDE5 inhibitors) (1) · ~30 min (1)

None (32) · 4–5 h (1) · 4–6 h (1) · Up to 36 h ("the weekend pill") (1) · ~4 h (1)

None (32) · 4–5 h (1) · ~17.5 h (1) · ~4 h (1) · ~5 h (1)

None (32) · Rapid absorption; absolute bioavailability not formally established (1) · Reasonable (not formally established as a percentage) (1) · ~15% (extensive hepatic first-pass) (1) · ~40% (1)